

Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 18, 1999.

A. Federal Reserve Bank of Dallas
(W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Eagle Bancshares, Inc.*, and *Fairfield Holdings, Inc.*, both of Fairfield, Texas; to engage *de novo* through their subsidiary, Texas Bank, S.S.B., Buffalo, Texas (in formation), in operating a savings association, pursuant to § 225.28(b)(4)(ii) of Regulation Y. Comments regarding this application must be received not later than August 27, 1999.

B. Federal Reserve Bank of San Francisco (Maria Villanueva, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Umpqua Holdings Corporation*, Roseburg, Oregon; to acquire Strand, Atkinson, Williams and York, Inc., Portland, Oregon, and thereby engage, to a limited extent, in underwriting and dealing in commercial paper, municipal revenue bonds, mortgage-related securities, and consumer-receivable related securities, *see Citicorp*, 73 *Fed. Res. Bull.* 473 (1987); acting as investment or financial advisor, pursuant to § 225.28(b)(6) of Regulation Y; providing securities brokerage, "riskless principal," private placement, and other agency transactional services, pursuant to § 225.28(b)(7)(i)-(iii), (v); and underwriting and dealing in obligations of the United States, general obligations of states and their political subdivisions, and other obligations that state member banks of the Federal Reserve System may underwrite and deal in under 12 U.S.C. 24 and 335, pursuant to § 225.28(b)(8)(i) of Regulation Y.

Board of Governors of the Federal Reserve System, July 29, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-19948 Filed 8-3-99; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Resources' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of the Treasury's current value of funds rate or the applicable rate determined from the "Schedule of Certified Interest Rates with Range of Maturities." This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the **Federal Register**.

The Secretary of the Treasury has certified a rate of 13¼ percent for the quarter ended June 30, 1999. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: July 27, 1999.

George Strader,

Deputy Assistant Secretary, Finance.

[FR Doc. 99-19941 Filed 8-3-99; 8:45 am]

BILLING CODE 4150-04-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case:

Deborah Arenburg, University of Maryland: Based on a report dated December 23, 1998, by the University of Maryland Investigation Committee, Ms. Arenburg's admissions, and information obtained by ORI during its oversight review, ORI finds that Ms. Arenburg, former Research Associate, Maryland Psychiatric Research Center, University of Maryland, engaged in scientific misconduct arising out of certain biomedical research supported by National Institute of Mental Health (NIMH), National Institutes of Health (NIH), grants.

Specifically, Ms. Arenburg was responsible for administering and scoring neuropsychological, neurological, and cognitive tests on patients during the course of two studies. These studies were entitled "Neural Basis of the Deficit Syndrome of Schizophrenia" (Study No. 1) and "Clozapine Treatment of Schizophrenic Outpatients" (Study No. 2) and were supported by the above-referenced grants. ORI finds that Ms. Arenburg failed to conduct the required tests on three patients in Study No. 1 and on ten to twelve patients in Study No. 2. Instead Ms. Arenburg fabricated the experimental records for those tests. Ms. Arenburg admits to fabricating the data.

The fabricated data was included in a publication, "Association Between Eye Tracking Disorder in Schizophrenia and Poor Sensory Integration," *American Journal of Psychiatry* 155(10):1352-1357, 1998. The principal investigator on the grants at issue reanalyzed the research data, eliminating all data produced by Ms. Arenburg, and found no significant difference in the results. A correction, including the reanalyzed data, was published in the *American Journal of Psychiatry* 156(4):603-609, 1999.

Ms. Arenburg has accepted the ORI finding and has entered into a Voluntary Settlement Agreement with ORI in which she has voluntarily agreed, for the three (3) year period beginning July 15, 1999:

(1) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) That any institution that submits an application for PHS support for a research project on which her participation is proposed or which uses her in any capacity on PHS supported research, or that submits a report of PHS-funded research in which she is involved, must concurrently submit a plan for supervision of her duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Ms. Arenburg's research contribution. The institution also must submit a copy of the supervisory plan to ORI.

FOR FURTHER INFORMATION CONTACT:
Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 99-19975 Filed 8-3-99; 8:45 am]

BILLING CODE 4160-17-P